Overall, BMS reported a 2% rise in second-quarter revenues to $11.9 billion, led once again by Opdivo and anti-thrombotic drug Eliquis (apixaban) but backed by a series of new products that ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.

It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Fangzhou Inc, a pioneer in internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb (BMS) China, a global biopharmaceutical company with a robust research and ...